Table 1

Demographic and clinical characteristics of patients with FTLD and controls

Variable FTLD Controls
bvFTD avPPA svPPA CBS PSP AD HC
Number134482751316363
Age, years64.5±8.067.7±8.864.0±8.265.8±7.672.9±7.475.5±8.165.4±12.1
Sex, female %58.243.859.352.951.631.720.6
Age at onset, years61.5±7.864.9±8.660.5±8.063.2±7.568.8±7.374.0±8.3
Disease duration, years2.9±2.82.8±2.63.3±2.22.5±1.84.1±2.81.5±1.7
Monogenic disease, n (%)20 (14.9)12 (25.0)0 (0.0)1 (2.0)0 (0.0)0 (0.0)
FTLD-CDR7.9±5.36.2±5.15.7±3.64.3±5.34.2±5.1
MMSE21.0±7.6518.7±9.921.7±8.324.7±4.624.1±7.019.5±4.7
Serum NfL (pg/mL)
mean±SEM43.0±2.454.6±3.933.3±5.236.5±3.830.4±4.932.7±3.614.2±3.5
95% CI38.3–47.846.9–62.323.0–43.629.1–44.020.7–40.125.6–39.97.4–21.1
Serum p-Tau 181 (pg/mL)
mean±SEM2.5±0.73.3±1.13.8±1.57.1±1.13.9±1.416.4±1.15.4±1.0
95% CI1.1–3.81.1–5.50.8–6.84.9–9.31.0–6.714.3–18.53.5–7.5
  • Results are expressed as mean±SD, unless otherwise specified. Monogenic disease: all GRN mutations, but three MAPT mutations (two bvFTD and one CBS).

  • AD, Alzheimer’s disease; avPPA, agrammatic variant of primary progressive aphasia; bvFTD, behavioural variant frontotemporal dementia; CBS, corticobasal syndrome; FTLD, frontotemporal lobar degeneration; FTLD-CDR, frontotemporal lobar degeneration-modified clinical dementia rating scale; HC, healthy controls; MMSE, Mini-Mental State Examination; NfL, neurofilament light chain; PSP, progressive supranuclear palsy; svPPA, semantic variant of primary progressive aphasia.